Classic Familial Adenomatous Polyposis Drugs Market Analysis

The market is segmented by drug type into monotherapy drugs and combination therapy drugs, out of which, the segment for monotherapy drugs is anticipated to hold the largest share in the classic familial adenomatous polyposis treatment market during the forecast period on account of their lesser number of adverse effects, reduced treatment costs, better tolerability and enhanced compliance with treatment. Moreover, on the basis of distribution channel, the hospital pharmacy segment is projected to occupy a significant market share in the near future, which can be credited to the increased interaction of prescribers and health professionals in hospitals, improved access to medical records of patients and better input in making effective prescribing decisions about drugs. 

Our in-depth analysis of the global classic familial adenomatous polyposis treatment market includes the following segments